868
Views
3
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias

, , , , , , , , , , , , & show all
Pages 111-112 | Received 25 Aug 2009, Accepted 01 Sep 2009, Published online: 20 Oct 2009

References

  • Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008;20:104–11.
  • Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, . Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531–41.
  • Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–78.
  • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.
  • Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: A growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007;16:566–71.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.